<PAGE>

                                  FORM 10-Q

                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D. C.  20549

[X]  Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended MARCH 31, 1998 or


[ ]  Transition report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934 For the transition period from ______ to ______


                                   1-9731
                            (COMMISSION FILE NO.)

                     ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
            (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


               DELAWARE                                72-0925679
     (STATE OR OTHER JURISDICTION         (I.R.S. EMPLOYER IDENTIFICATION NO.)
   OF INCORPORATION OR  ORGANIZATION)


        5910 COURTYARD DRIVE #300
              AUSTIN, TEXAS                             78731
  (ADDRESS OF PRINCIPAL EXECUTIVE OFFICE)             (ZIP CODE)


                               (512) 343-6912
             (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)


Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 
1934 during the preceding 12 months (or for such shorter period that the 
registrant was required to file such reports), and (2) has been subject to 
such filing requirements for the past 90 days.  Yes  /X/  No / /.

As of May 10, 1998 there were 3,563,101 shares of common stock outstanding.

This report consists of  10 pages.

<PAGE>

                     ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

                              TABLE OF CONTENTS

                                  FORM 10-Q

                               March 31, 1998

<TABLE>
<S>                                                                          <C>
PART I - FINANCIAL INFORMATION . . . . . . . . . . . . . . . . . . . . . . .   3

     Item 1.  Financial Statements . . . . . . . . . . . . . . . . . . . . .   3

CONSOLIDATED BALANCE SHEETS. . . . . . . . . . . . . . . . . . . . . . . . .   3
     CONSOLIDATED STATEMENTS OF OPERATIONS . . . . . . . . . . . . . . . . .   4
     CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY. . . . . . .   5
     CONSOLIDATED STATEMENTS OF CASH FLOWS . . . . . . . . . . . . . . . . .   6
     SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS . . . . . . . .   7
     Item 2.  Management's Discussion and Analysis of Financial
              Condition and Results of Operations. . . . . . . . . . . . . .   8

PART II - OTHER INFORMATION. . . . . . . . . . . . . . . . . . . . . . . . .  10

     Item 1.  Legal Proceedings - none . . . . . . . . . . . . . . . . . . .  10

     Item 2.  Changes in Securities - none . . . . . . . . . . . . . . . . .  10
     Item 3.  Defaults Upon Senior Securities - none . . . . . . . . . . . .  10
     Item 4.  Submission of Matters to a Vote of Security Holders - none . .  10
     Item 5.  Other Information - none . . . . . . . . . . . . . . . . . . .  10
     Item 6.  Exhibits and Reports on Form 8-K - none. . . . . . . . . . . .  10
     SIGNATURES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  10
</TABLE>

                                 Page 2 of 10

<PAGE>

                            PART I - FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS
<TABLE>
                                       ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                                   CONSOLIDATED BALANCE SHEETS

                                                                                               March 31,        December 31,    
                                          ASSETS                                                 1998               1997        
                                                                                          ------------------  ----------------- 
CURRENT ASSETS:                                                                              (UNAUDITED)    
<S>                                                                                       <C>                 <C>
  Cash and cash equivalents.............................................................. $          147,241  $         214,938 
  Trade and other accounts receivable, net of allowance for doubtful accounts............
        of $61,318 ......................................................................          2,272,968          2,397,269 
  Inventories, net.......................................................................          2,132,452          2,001,123 
  Income Taxes Recoverable...............................................................            262,808            262,810 
  Other current assets...................................................................            139,683             63,861 
                                                                                          ------------------  ----------------- 
    Total current assets.................................................................          4,955,152          4,940,001 

Property and equipment, net of accumulated depreciation of $2,489,507 and $2,322,218.....          4,053,157          4,195,167 
Patent and software development costs, net of accumulated amortization of $430,192 and...
       $422,858..........................................................................             84,245             85,667 
Goodwill, net of accumulated amortization of $671,454 and $635,476.......................          1,989,619          2,025,597 
Deferred income taxes, net...............................................................            458,923            458,923 
Other assets.............................................................................             45,960            127,055 
                                                                                          ------------------  ----------------- 
    Total assets......................................................................... $       11,587,056  $      11,832,410 
                                                                                          ------------------  ----------------- 
                                                                                          ------------------  ----------------- 
                           LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
  Borrowings under revolving credit facilities........................................... $          412,211  $         467,135 
  Current maturities of bonds payable and long-term debt.................................            220,442            320,328 
  Current maturities of capital lease obligations........................................             64,923            100,371 
  Accounts payable.......................................................................            984,224          1,091,550 
  Income taxes payable...................................................................             91,460             -
  Accrued liabilities and other liabilities..............................................            554,727            667,172 
                                                                                          ------------------  ----------------- 
    Total current liabilities............................................................          2,327,987          2,646,556 

Bonds payable, and other long-term debt, net of current maturities.......................            965,086            953,086 
Capital lease obligations, net of current maturities.....................................             92,081             92,082 
Deferred revenue.........................................................................             43,230             53,896 
                                                                                          ------------------  ----------------- 
    Total liabilities....................................................................          3,428,384          3,745,620 
                                                                                          ------------------  ----------------- 
Shareholders' equity:
  Preferred stock, $1 par value; 2,000,000 shares authorized, none issued................           -                    -  
  Common stock, $.01 par value; 10,000,000 shares authorized;
      3,679,216 issued...................................................................             36,792             36,792 
Additional paid-in capital...............................................................          8,909,307          8,909,307 
Treasury stock, 116,115 shares at cost...................................................           (878,787)          (878,787)
Unearned ESOP compensation...............................................................            (71,420)           (82,134)
Retained earnings........................................................................            162,780            101,612 
                                                                                          ------------------  ----------------- 
    Total shareholders' equity...........................................................          8,158,672          8,086,790 
                                                                                          ------------------  ----------------- 
    Total liabilities and shareholders' equity........................................... $       11,587,056  $      11,832,410 
                                                                                          ------------------  ----------------- 
                                                                                          ------------------  ----------------- 
                      The accompanying notes are an integral part of the consolidated financial statements.
</TABLE>
                                 Page 3 of 10

<PAGE>
<TABLE>
                                        ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                               CONSOLIDATED STATEMENTS  OF OPERATIONS
                                                            (Unaudited)

                                                          Three Months Ended March 31,    
                                                      ------------------------------------
                                                            1998                1997      
                                                      ----------------    ----------------
<S>                                                   <C>                 <C>
Net sales.....................................        $     2,429,112     $     3,873,531 
Cost of sales.................................              1,436,231           2,738,135 
                                                      ---------------     --------------- 
Gross profit..................................                992,881           1,135,396 
                                                      ---------------     --------------- 
Selling and marketing.........................                 96,962             140,954 
General and administrative....................                537,479             583,544 
Research and development......................                100,048              46,219 
Amortization of goodwill......................                 28,716              28,716 
                                                      ---------------     --------------- 
Total expenses................................                763,205             799,433 
                                                      ---------------     --------------- 
Income from operations........................                229,676             335,963 

Other income (expense):
  Interest expense............................                (31,213)            (52,195)
Other.........................................                (26,757)             (3,755)
                                                      ---------------     --------------- 
Income before income taxes....................                171,706             280,013 
Income taxes..................................                110,538             113,174 
                                                      ---------------     --------------- 
Net income....................................        $        61,168     $       166,839 
                                                      ---------------     --------------- 
                                                      ---------------     --------------- 
Basic & diluted net income per share..........        $          0.02     $          0.05 
                                                      ---------------     --------------- 
                                                      ---------------     --------------- 
Weighted average number of common
  and dilutive common equivalent
  shares outstanding..........................              3,563,101           3,607,614 
                                                      ---------------     --------------- 
                                                      ---------------     --------------- 

                       The accompanying notes are an integral part of the consolidated financial statements.
</TABLE>


                                 Page 4 of 10

<PAGE>
<TABLE>
                                        ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                     CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
                                                             (Unaudited)

                                                                                                Net        Retained
                              Common Shares          Additional                   Unearned   Unrealized    Earnings
                           ---------------------      Paid-in       Treasury        ESOP     Securities  (Accumulated
                            Number        Amount      Capital         Stock     Compensation    Gains       Deficit)        Total  
                           ---------     -------     ----------     ---------   ------------   --------    -----------   ----------
<S>                        <C>           <C>         <C>            <C>         <C>           <C>         <C>            <C>       
December 31, 1997.......   3,563,101     $36,792     $8,909,307     ($878,787)      ($82,134)      -           101,612   $8,086,790
ESOP payments...........                                                              10,714                                 10,714
Net income..............                                                                                        61,168       61,168
                           ---------     -------     ----------     ---------   ------------   --------    -----------   ----------
March 31, 1998             3,563,101     $36,792     $8,909,307     ($878,787)      ($71,420)        $0       $162,780   $8,158,672
                           ---------     -------     ----------     ---------   ------------   --------    -----------   ----------
                           ---------     -------     ----------     ---------   ------------   --------    -----------   ----------

                       The accompanying notes are an integral part of the consolidated financial statements.
</TABLE>

                                 Page 5 of 10

<PAGE>
<TABLE>
                                        ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                               CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                            (Unaudited)
                                                                                              Three Months Ended March 31,         
                                                                                      ---------------------------------------------
                                                                                               1998                  1997          
                                                                                      ---------------------- ----------------------
<S>                                                                                   <C>                    <C>                   
Cash flows from operating activities:
  Net income........................................................................  $              61,168 $             166,839
  Adjustments to reconcile net income to net cash provided by operating
  activities:
Depreciation........................................................................                167,289               132,659 
Amortization........................................................................                 55,312                46,250 
  Changes in assets and liabilities:
    Trade and other accounts receivable, net........................................                124,301             1,016,357 
    Deposits, prepaid expenses and other current assets.............................                  4,180                (8,427)
    Inventories.....................................................................               (131,329)               81,766 
    Accounts payable, accrued liabilities and other current liabilities.............               (219,771)             (333,048)
    Income taxes payable............................................................                 91,460               136,931 
    Deferred revenue................................................................                (10,666)                  334 
   Other assets ....................................................................                  1,095                     0 
                                                                                      --------------------- --------------------- 
Net cash provided by operating activities...........................................                143,039             1,239,661 
                                                                                      --------------------- --------------------- 
Cash flows from investing activities:
  Capital expenditures .............................................................                (31,191)             (268,798)
  Deposits on capital equipment and other...........................................                      0              (412,816)
  Patent and software development expenditures......................................                      0                (3,004)
                                                                                      --------------------- --------------------- 
    Net cash used in investing activities...........................................                (31,191)             (684,618)
                                                                                      --------------------- --------------------- 
Cash flows from financing activities:
  Net repayments of revolving credit facilities.....................................                (54,924)             (665,745)
  Reduction of unearned ESOP compensation...........................................                 10,714                10,714 
  Principal payments on long-term debt, net.........................................               (135,335)             (102,660)
                                                                                      --------------------- --------------------- 
    Net cash used in financing activities...........................................               (179,545)             (757,691)
                                                                                      --------------------- --------------------- 
Net increase (decrease) in cash and cash equivalents................................                (67,697)             (202,648)
Cash and cash equivalents at beginning of period....................................                214,938               232,135 
                                                                                      --------------------- --------------------- 
Cash and cash equivalents at end of period..........................................  $             147,241 $              29,487 
                                                                                      --------------------- --------------------- 
                                                                                      --------------------- --------------------- 

                       The accompanying notes are an integral part of the consolidated financial statements.
</TABLE>

                                 Page 6 of 10

<PAGE>

SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS

     The unaudited interim consolidated financial statements and related 
notes have been prepared pursuant to the rules and regulations of the 
Securities and Exchange Commission.  Accordingly, certain information and 
footnote disclosures normally included in financial statements prepared in 
accordance with generally accepted accounting principles have been omitted 
pursuant to such rules and regulations.  The accompanying unaudited interim 
consolidated financial statements and related notes should be read in 
conjunction with the consolidated financial statements and notes thereto 
included in the Company's most recent Form 10-K covering the year ended 
December 31, 1997.

     The information furnished reflects, in the opinion of the management of 
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a 
fair presentation of the financial results for the interim period presented.

     Interim results are subject to year-end adjustments and audit by 
independent certified public accountants.

INVENTORIES:

     Inventories consist of the following as of:
<TABLE>
                                                                       March 31,        December 31,
                                                                       ---------        ------------
                                                                         1998               1997
<S>                                                                   <C>               <C>         
Raw materials  . . . . . . . . . . . . . . . . . . . . . . . . .      $  306,485        $  288,255
Work-in-process. . . . . . . . . . . . . . . . . . . . . . . . .         202,604           282,929
Finished goods . . . . . . . . . . . . . . . . . . . . . . . . .       2,428,411         2,250,549
                                                                      ----------        ----------
     Total     . . . . . . . . . . . . . . . . . . . . . . . . .       2,937,500         2,821,733
Allowance for slow-moving inventories. . . . . . . . . . . . . .        (805,048)         (820,610)
                                                                      ----------        ----------
     Total     . . . . . . . . . . . . . . . . . . . . . . . . .      $2,132,452        $2,001,123
                                                                      ----------        ----------
                                                                      ----------        ----------
</TABLE>

RECENT PRONOUNCEMENTS:

     In February of 1997, the Financial Accounting Standards Board issued 
Statement of Financial Accounting Standards No. 128 "Earnings Per Share" 
("SFAS No. 128") which establishes standards for computing and presenting 
earnings per share.  SFAS No. 128 is effective for fiscal years ending after 
December 15, 1997.  Management does not believe the implementation of SFAS 
No. 128 will have a material effect on its financial statements.

     In February 1997, the FASB issued Statement of Financial Accounting 
Standards No. 129 "Disclosure of Information About Capital Structure" ("SFAS 
No. 129") which establishes disclosure requirements for an entity's capital 
structure.  SFAS No. 129 is effective for fiscal years ending after December 
15, 1997.  Management does not believe the implementation of SFAS No. 129 
will have a material effect on its financial statements.  

     In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive 
Income," which establishes standards for reporting and display of 
comprehensive income and its components in a full set of general-purpose 
financial statements. SFAS No. 130 is effective for fiscal years beginning 
after December 15, 1997.

     Also in June 1997, the FASB issued SFAS No. 131, "Disclosures about 
Segments of an Enterprise and Related Information," which establishes 
standards for the way the public business enterprises report information 
about operating segments in annual financial statements and requires that 
those enterprises report selected information about operating segments in 
interim financial reports issued to shareholders.  It also establishes 
standards for related disclosures about products and services, geographic 
areas, and major customers. SFAS No. 131 is effective for financial 
statements for periods beginning after December 15, 1997.

     NET INCOME PER SHARE DATA  Earnings per share is calculated by dividing 
the net income (loss) by the weighted average number of common shares and 
common share equivalents outstanding during the year.  In 1997 the Company 
adopted SFAS No. 128 "Earnings Per Share" which requires the Company to 
present its basic earnings per share and diluted earnings per share, and 
certain other earnings per share disclosures for each year presented.  Basic 
earnings per share is computed by dividing income available to common 
shareholders by the weighted average number of common shares outstanding.  
The computation of diluted loss per share is similar to the computation of 
basic loss per share except that the denominator is increased to include the 
number of additional common shares that would have been outstanding if the 
dilutive potential common shares had been issued.  In addition, the numerator 
is adjusted for any changes in income or loss that would result from the 
assumed conversions of those potential shares. The Company adopted SFAS No. 
128 for the year ended December 31, 1997. Previously reported EPS have been 
restated to conform to SFAS No. 128.

                                 Page 7 of 10

<PAGE>

     Basic and diluted EPS computation for the three months ended March 31, 
1998 and 1997 are as follows:
<TABLE>
                                                                 ----------------------------
                                                                 Three Months Ended March 31,
                                                                    1998             1997    
                                                                 ----------------------------
     <S>                                                         <C>            <C>
     BASIC EPS
     Net income available to common stockholders . . . . .          61,169       $  166,839
     Weighted average common shares outstanding. . . . . .       3,563,101        3,607,614
     Basic EPS . . . . . . . . . . . . . . . . . . . . . .              02       $      .05

     DILUTED EPS
     Net income available to common stockholders . . . . .          61,169          166,839
     Weighted average common share outstanding . . . . . .       3,563,101        3,607,614
     Assumed conversion of common shares issuable
     under stock option plan.. . . . . . . . . . . . . . .               -
     Weighted average common and common equivalent
     shares outstanding. . . . . . . . . . . . . . . . . .       3,563,101        3,607,614
                Diluted EPS. . . . . . . . . . . . . . . .            0.02       $     0.05
</TABLE>

     In 1998 and 1997 the Company had common stock options outstanding during 
the years which were not included in the diluted earnings per share 
calculation because they would have been antidulutive.  As of March 31, 1998 
and 1997, the Company had 177,000 and 197,000 options outstanding, 
respectively.

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND 
          RESULTS OF OPERATIONS

LIQUIDITY AND CAPITAL RESOURCES             

     At March 31, 1998, the Company had working capital of approximately 
$2,547,000.  At March 31, 1998, the Company had a $3,500,000 working capital 
line of credit with a bank, collateralized by accounts receivable and 
inventory of ART and Micron Products Inc., which bears interest at prime plus 
 .75% (9.25% at March 31, 1998).  The working capital line of credit matures 
December 15, 1999 and had an outstanding balance of approximately $412,000 at 
March 31, 1998. The Company's lines of credit are its primary source of 
operating funds and liquidity.  

     Capital expenditures during the first three months of 1998 were 
approximately $42,000 compared to $269,000 in 1997.   Capital expenditures 
decreased in the first quarter of 1998 compared to 1997 because Micron 
completed its wastewater treatment and filtration system in l997.  Capital 
expenditures are expected to be lower in 1998 than they were in 1997.  Normal 
capital expenditures are funded from operating cash flows.

RESULTS OF OPERATIONS

     REVENUES for the first quarter ended March 31, 1998 decreased 
approximately 37% when compared to the first quarter ended March 31, 1997.  
The reason for the reduced sales revenues is that in 1997 approximately 
$730,000 in electrophysiology ("EP") product sales was recorded for products 
ordered in 1996 and shipped in 1997.  1996 was the final year ART acted as 
the exclusive distributor for EP products under its contract with their 
manufacturer, Prucka Engineering, Inc.  EP product sales and cost of sales 
approximated $730,000 and $678,000 respectively for the three months ended 
March 31, 1997.  During 1998, ART will receive a 4% commission on net sales 
of EP systems and accessories sold anywhere in the world, up to a ceiling of 
$10,000,000 in total annual net sales. From January 1, 1999 through December 
31, 2002, ART will receive a commission of 3% of the net sales of CardioLab 
systems sold anywhere in the world, up to a ceiling of $10,000,000 in total 
net sales.  For revenues attributable to Prucka products that exceed 
$10,000,000 in any year, ART will be entitled to receive 25% of the 
commission rate in effect that respective year. 

     Revenues from sales of electrocardiographic ("ECG") sensors decreased 
21% for the quarter ended March 31, 1998, as compared to the same period in 
1997 due to a deferral of orders in January 1998 caused by uncertainty in the 
silver market.  

                                 Page 8 of 10

<PAGE>

February and March sales returned to normal levels. The sales mix for the 
Company continues with ECG sensors making up a greater proportion of sales 
and the related cost of sales.

     Domestic and foreign sales for the first quarter are as follows:
<TABLE>
                                                            FIRST QUARTER 
                                                            ------------- 
                                                  1998         %           1997          %
                                              ----------   ------      -----------    -----
          <S>                               <C>            <C>        <C>             <C> 
          Domestic . . . . . . . . . .      $  1,357,476       56     $  2,636,889       68
          Foreign. . . . . . . . . . .         1,071,636       44        1,236,642       32
                                              ----------   ------      -----------    -----
          Total. . . . . . . . . . . .      $  2,429,112      100     $  3,873,531      100
                                              ----------   ------      -----------    -----
                                              ----------   ------      -----------    -----
</TABLE>

     COST OF SALES decreased significantly for the quarter  ended March 31, 
1998, as compared to the same period in 1997 because of the absence of EP 
sales as noted above.  Overhead costs at Micron for the first quarter ended 
March 31, 1998, decreased as compared to the same period of the prior year 
due to lower than normal repairs and maintenance, utilities and waste 
treatment expenses. Overhead costs for ART have remained consistent for the 
three months ended March 31, 1998 as compared to 1997.  Cost of sales as a 
percent of sales is not expected to change significantly for the remainder of 
the year.  

     SELLING AND MARKETING expenses remained consistent as a percent of sales 
during the first quarter ended March 31, 1998 as compared to the same period 
for 1997. The primary components of marketing and selling expenses for the 
first quarter ended March 31, 1998 are salaries and trade show expenses.  The 
current level of marketing operations is expected to increase during the 
remainder of the year as a result of  worldwide marketing and sales efforts.  
   

     GENERAL AND ADMINISTRATIVE expenses decreased  $46,000 in the first 
quarter ended March 31, 1998, as compared to 1997 primarily due to lower 
insurance premiums and a decrease in environmental consultation fees.  The 
primary components of general and administrative expenses are salaries and 
related payroll taxes and benefits, environmental monitoring expenses, 
professional fees, and insurance costs.  General and administrative expenses 
are expected to continue at this level for the remainder of the year.

     RESEARCH AND DEVELOPMENT expenses increased significantly by $54,000 for 
the first quarter ended March 31, 1998, as compared to the same period in 
1997. The increase is due primarily to development costs associated with 
converting the signal averaging software from DOS to Windows and with 
converting the Cath Lab software to a Windows NT platform.  Salaries and 
related costs also increased during the first quarter of 1998. 

SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

     Forward looking statements made herein are based on current expectations 
of the Company that involves a number of risks and uncertainties and should 
not be considered as guarantees of future performance.  These statements are 
made under the Safe Harbor Provisions of the Private Securities Litigation 
Reform Act of 1995.  The factors that could cause actual results to differ 
materially include: interruptions or cancellation of existing contracts, 
impact of competitive products and pricing, product demand and market 
acceptance risks, the presence of competitors with greater financial 
resources than the Company, product development and commercialization risks 
and an inability to arrange additional debt or equity financing.

                                 Page 9 of 10

<PAGE>

                         PART II - OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS - NONE

ITEM 2.  CHANGES IN SECURITIES - NONE

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES - NONE

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE

ITEM 5.  OTHER INFORMATION - NONE 

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K - NONE


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.

                              ARRHYTHMIA RESEARCH TECHNOLOGY, INC.


                              /s/ Sid Barbanel



                              Sid Barbanel, President and
                              Chief Executive Officer



                              /s/  Anthony A. Cetrone,
                              President, Micron Products Inc.
                              Chairman of the Board

May 13, 1998   



                                 Page 10 of 10